Clinical Trial Update: A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses the safety and immunogenicity of the Moderna COVID-19 vaccine (mRNA-1273) in patients with solid tumors and hematologic malignancies…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Leukemia
• Lymphoma
• Multiple Myeloma
• Solid Tumor Malignancy

Drugs mentioned

• Moderna COVID-19 vaccine (mRNA-1273) (mRNA-1273)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Status: COMPLETED | Results posted: 2024-08-27